Galapagos, e-therapeutics Partner to Identify Compounds to Treat Fibrotic Diseases

Galapagos, e-therapeutics Partner to Identify Compounds to Treat Fibrotic Diseases

Galapagos and e-therapeutics are partnering to investigate mechanisms involved in idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions and to select potential therapeutic candidates. The collaboration will combine Galapagos’ extensive knowledge on IPF and fibrosis with e-therapeutics’ Network-driven Drug Discovery (NDD) platform for examining disease mechanisms…

Recovering from an Acute Health Setback Is Challenging

Many Pulmonary Fibrosis News readers know that during the last few months, I have had several acute illnesses. As a patient living with idiopathic pulmonary fibrosis (IPF), a life-threatening lung disease, I ended up quite sick as a result. Since mid-November, I have been recovering from pneumonia, influenza A, strep…